Molecular structure of BAY 41-2272, CAS Number: 256376-24-6
BAY 41-2272 (CAS 256376-24-6)
See product citations (4)
Alternate Names:
3-(4-Amino-5-cyclopropylpyrimidin-2-yl)-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine
Application:
BAY 41-2272 is a pyrazolopyridinylpyrimidine compound with potent stimulator effects on soluble guanylate cyclase
CAS Number:
256376-24-6
Purity:
≥98%
Molecular Weight:
360.39
Molecular Formula:
C20H17FN6
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
BAY 41-2272 is a pyrazolopyridinylpyrimidine compound with selective and potent stimulator effects on soluble guanylate cyclase (sGC). This product sensitizes sGC to nitric oxide (NO), its physiological stimulator, and contains antiplatelet activity. BAY 41-2272 is an inhibitor of GCS.
BAY 41-2272 (CAS 256376-24-6) References
- NO-independent regulatory site on soluble guanylate cyclase. | Stasch, JP., et al. 2001. Nature. 410: 212-5. PMID: 11242081
- NO-independent regulatory site of direct sGC stimulators like YC-1 and BAY 41-2272. | Becker, EM., et al. 2001. BMC Pharmacol. 1: 13. PMID: 11801189
- Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure. | Boerrigter, G., et al. 2003. Circulation. 107: 686-9. PMID: 12578869
- Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease. | Boerrigter, G. and Burnett, JC. 2007. Cardiovasc Drug Rev. 25: 30-45. PMID: 17445086
- BAY 41-2272 inhibits the development of chronic hypoxic pulmonary hypertension in rats. | Thorsen, LB., et al. 2010. Eur J Pharmacol. 647: 147-54. PMID: 20828552
- BAY 41-2272, a soluble guanylate cyclase agonist, activates human mononuclear phagocytes. | Soeiro-Pereira, PV., et al. 2012. Br J Pharmacol. 166: 1617-30. PMID: 22044316
- BAY 41-2272 activates host defence against local and disseminated Candida albicans infections. | Soeiro-Pereira, PV., et al. 2015. Mem Inst Oswaldo Cruz. 110: 75-85. PMID: 25742266
- Soluble Guanylate Cyclase Modulators, BAY 41-2272 and BAY 60-2770, Inhibit Human and Rabbit Prostate Contractility. | Calmasini, FB., et al. 2016. Urology. 94: 312.e9-312.e15. PMID: 27131967
- BAY 41-2272 Treatment Improves Acetylcholine-Induced Aortic Relaxation in L-NAME Hypertensive Rats. | Prawez, S., et al. 2016. Int J Angiol. 25: 235-240. PMID: 27895434
- BAY 41-2272 inhibits human neutrophil functions. | Rosa, PVF., et al. 2019. Int Immunopharmacol. 75: 105767. PMID: 31376626
- BAY 41-2272 inhibits human T lymphocyte functions. | Carvalho, MUWB., et al. 2019. Int Immunopharmacol. 77: 105976. PMID: 31732450
- BAY 41-2272 Attenuates CTGF Expression via sGC/cGMP-Independent Pathway in TGFβ1-Activated Hepatic Stellate Cells. | Chen, PJ., et al. 2020. Biomedicines. 8: PMID: 32899801
- Mapping of the sGC Stimulator BAY 41-2272 Binding Site on H-NOX Domain and Its Regulation by the Redox State of the Heme. | Makrynitsa, GI., et al. 2022. Front Cell Dev Biol. 10: 925457. PMID: 35784456
Inhibitor of:
Clca6, GCS, LPPR2, OPN1MW2, and VASP.Activator of:
acrogranin, ARK-2, C20orf152, C22orf13, CaMKIIδ, cGKI α, Dlx-6, GCAP1, GCS-α-2, GCS-β-1, GCS-β-2, HOP-1, LIR_6, LOC643037, Mesogenin 1, MRP-L32, NPR-B, NPY2-R, Olfr715, Olfr716, Ost1, Otospiralin, PDZK2, sGC α1, sGC α2, sGC α2I, sGC β1, sGC β2, smoothelin, TLR7, V1RE1, and V1RE13.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
BAY 41-2272, 5 mg | sc-202491 | 5 mg | $233.00 | |||
BAY 41-2272, 25 mg | sc-202491A | 25 mg | $714.00 |